Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI), in patients (pts) with HER2 aberration-positive solid tumors: Updated Phase Ia data from Beamion LUNG-1, including progression-free survival (PFS) data.
Wednesday, June 19, 2024
Dr. Minal Barve
Click above link to view abstract, login required to view video presentation.
Related Abstracts
Discover more abstracts for our trials.